Ultragenyx Pharmaceutical Inc. buy Royal Bank of Canada
Start price
06.11.24
/
50%
€47.00
Target price
06.11.25
€71.64
Performance (%)
-42.98%
End price
07.11.25
€26.80
Summary
This prediction ended on 07.11.25 with a price of €26.80. The BUY prediction by Royal_Bank_of_Canada for Ultragenyx Pharmaceutical Inc. performed very badly with a performance of -42.98%. Royal_Bank_of_Canada has a follow-up prediction for Ultragenyx Pharmaceutical Inc. where he still thinks Ultragenyx Pharmaceutical Inc. is a Buy. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -6.430% | -6.430% | -0.720% |
| iShares Core DAX® | 1.717% | 3.368% | 5.887% |
| iShares Nasdaq 100 | -4.565% | -4.238% | 21.386% |
| iShares Nikkei 225® | -7.120% | -11.869% | 42.357% |
| iShares S&P 500 | -0.894% | 1.687% | 19.495% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Ultragenyx Pharmaceutical Inc. diskutieren
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $77.00 price target on the stock.
Ratings data for RARE provided by MarketBeat
In the thread Trading Ultragenyx Pharmaceutical Inc.
Die von Royal_Bank_of_Canada gewählte maximale Laufzeit wurde überschritten
Current prediction by Royal_Bank_of_Canada for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€31.15
07.07.26
07.07.26
€34.97
07.07.27
07.07.27
-26.81%
28.07.26
28.07.26
Stopped prediction by Royal_Bank_of_Canada for Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€49.00
26.09.24
26.09.24
€69.10
26.09.25
26.09.25
-49.39%
27.09.25
27.09.25
Ultragenyx Pharmaceutical Inc.
Start price
Target price
Perf. (%)
€41.20
22.04.24
22.04.24
€72.35
22.04.25
22.04.25
-22.82%
23.04.25
23.04.25